Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reiterated by analysts at Bank of America Corp. in a research report issued to clients and investors on Tuesday, AnalystRatingsNetwork reports. They currently have a GBX 1,300 ($21.28) price objective on the stock. Bank of America Corp.’s target price points to a potential upside of 8.06% from the stock’s previous close.
Shares of Hikma Pharmaceuticals (LON:HIK) opened at 1205.00 on Tuesday. Hikma Pharmaceuticals has a 52-week low of GBX 739.00 and a 52-week high of GBX 1236.00. The stock’s 50-day moving average is GBX 1181. and its 200-day moving average is GBX 1067.. The company’s market cap is £2.382 billion.
HIK has been the subject of a number of other recent research reports. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Hikma Pharmaceuticals from GBX 1,180 ($19.32) to GBX 1,200 ($19.65) in a research note to investors on Wednesday, November 27th. They now have a “neutral” rating on the stock. Separately, analysts at UBS AG reiterated a “neutral” rating on shares of Hikma Pharmaceuticals in a research note to investors on Tuesday, November 26th. They now have a GBX 1,050 ($17.19) price target on the stock. Finally, analysts at Panmure Gordon raised their price target on shares of Hikma Pharmaceuticals from GBX 1,300 ($21.28) to GBX 1,350 ($22.10) in a research note to investors on Friday, November 8th. They now have a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of GBX 1,171.26 ($19.18).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.